Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10089235 | 0.82 | FOLH1 (0.69) | SGMS2MEN1KMT2AFOLH1 | |
| SCHEMBL23796838 | 0.82 | SGMS2 (0.57) | SGMS2MEN1KMT2AGAALRRK2 | |
| SCHEMBL30032645 | 0.82 | SGMS2 (0.57) | SGMS2MEN1KMT2AGAALRRK2 | |
| SCHEMBL23809749 | 0.81 | MEN1 (0.57) | SGMS2NR1H4MEN1KMT2ANPC1 | |
| SCHEMBL23803642 | 0.81 | GAA (0.60) | SGMS2MEN1KMT2AGAALRRK2 | |
| SCHEMBL30031887 | 0.81 | GAA (0.60) | SGMS2MEN1KMT2AGAALRRK2 | |
| SCHEMBL23809700 | 0.79 | MEN1 (0.50) | SGMS2MEN1KMT2AGAALRRK2 | |
| SCHEMBL30892473 | 0.79 | FOLH1 (0.65) | SGMS2MEN1KMT2AFOLH1 | |
| SCHEMBL24983867 | 0.79 | FOLH1 (0.65) | SGMS2MEN1KMT2AFOLH1 | |
| SCHEMBL23817115 | 0.78 | SGMS2 (0.67) | SGMS2MEN1KMT2AGAALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2023-05-18 | — | — | US | disclosed |
| WO-2021180655-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2021-09-16 | — | — | WO | disclosed |
| EP-3878837-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM Pharma SA (CH) | 2021-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | HRH4, NCOA4, HRH3 | SGMS2 492/4885NR1H4 15/4885MEN1 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.